At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
gemcitabine +3 moredrug
Likely dose
placebo 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating gemcitabine, placebo, and 2 other interventions for Pancreatic Cancer and Metastatic Pancreatic Cancer. Completed, enrolled 109 participants across 39 sites.
Detailed Summary
This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Metastatic Pancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartAug 2008
Primary CompletionJun 2010
Study CompletionMay 2011
TodayJul 2026
First PostedJul 3, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.0 years ago
Interventions
gemcitabinedrug
Gemcitabine: per package insert.
placebodrug
placebo: 100 mg tablets, 400 mg/day
Erlotinibdrug
Erlotinib - per package insert.
apricoxibdrug
apricoxib: 100mg tablets, given orally